Regeneron up 7% following Dupixent data, Raymond James upgrade
JaysonPhotography


A combination of positive late-stage trial results for Dupixent (dupilumab) in chronic obstructive pulmonary disease (COPD) and a Street upgrade has propelled Regeneron Pharmaceuticals (NASDAQ:REGN) 7% higher in Thursday morning trading.
Earlier Thursday, Regeneron's (REGN) partner, Sanofi (SNY), said that Dupixent could potentially become the first biologic medicine approved for COPD based on a reduction in exacerbations.

Raymond James upgraded Regeneron (REGN) to market perform from underperform on the news. The firm does not have a target price.
Analyst Dane Leone said that because the setup of the BOREAS study is more challenging than the study period for the confirmatory trial NOTUS, it bodes well for the latter trial's readout in 2024.
Leone said that while there are limited clinical downside catalysts for the remainder of the year, the outlook for Vabysmo, Eylea, and high-dose Eylea will weigh on the stock.
Read why Seeking Alpha contributors Derek Pitman and Betsy Yang rate Regeneron (REGN) a hold.